As of today, there’s $200 million in fresh investment money looking for a new home. But you have to dream big. The funding is meant for companies that “have the potential to generate $100 million a year in revenue.”

So says University City-based 1315 Capital. The growth-equity firm announced Wednesday the closing of a $200 million fund aimed at commercial-stage pharma, medical and healthcare services companies.

An undisclosed group of individual investors, foundations, state and corporate pension funds raised the stately total.

“Consolidation within healthcare has provided opportunities for innovation, particularly in niche markets,” said 1315 Capital partner Adele Oliva. “We are committed to working with exceptional management teams to fill needs in the healthcare market and build value for our investors.”

Oliva launched 1315 Capital with Michael Koby in 2014. The St. Joseph’s University grad was listed by Forbes as a top-100 technology investor worldwide. She has been in the equity investment space for the past 19 years.

There are currently only three companies in 1315’s portfolio: Encore Dermatology in Malvern, Pa., JDS Therapeutics in Purchase, N.Y., and Onkos Surgical in Parsippany, N.J.